| Project/Area Number |
22591517
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Nagoya University |
|---|
Principal Investigator |
TAKEDA Shin 名古屋大学, 医学系研究科, 准教授 (20314015)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SUGIMOTO Hiroyuki 名古屋大学, 大学院・医学系研究科, 講師 (20437007)
FUJII Tsutomu 名古屋大学, 医学部附属病院, 助教 (60566967)
NAKAO Akimasa 名古屋大学, 大学院・医学系研究科, 助教 (70167542)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2012: ¥520,000 (Direct Cost: ¥400,000、Indirect Cost: ¥120,000)
Fiscal Year 2011: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2010: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | pancreatic cancer / オーダーメード医療 / 抗癌剤感受性遺伝子 / TS / DPD / adjuvant chemotherapy / S-1 / gemcitabine / OPRT / microdissection / RNA expression |
|---|
| Research Abstract |
Gemcitabine or S-1 is now considered to be the standard adjuvant therapy for advanced pancreatic cancer. Randomized controlled studies by JASPAC have demonstrated that S-1 is more effective in prolonging survival in patients with advanced pancreatic cancer in 2013. However, the indications due to biomarkers are not reported. Therefore, our aim is to clarify which biomarkers is important in gemcitabine or S-1 as adjuvant therapy for the resectable pancreatic cancer. These results suggest that the cases with TS positive or DPD negative might be predictor for the response to S-1.
|
